NCT05576272 2023-11-22
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
Clinical Trials
10 trialsNCT04074564 2023-10-23
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase EARLY_PHASE1 Unknown
NCT05214976 2022-12-22
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT05042375 2022-11-17
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04426955 2021-09-16
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03668496 2021-03-15
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03363555 2020-06-18
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04203485 2020-05-08
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03393416 2019-08-29
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
HRYZ Biotech Co.
Phase 1 Unknown